GlassScriptPhysician profile
Melanie Hughes
NPI 1386151504
$1,230.06
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,213 · 2022: $17.08.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $237.46 | 2021 | |
| Astellas Pharma US INC | $137.37 | 2021 | |
| Amgen INC. | $116.94 | 2021 | |
| Daiichi Sankyo INC. | $81.63 | 2021 | |
| Abbvie INC. | $79.96 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $67.54 | 2021 | |
| Lilly USA, LLC | $65.84 | 2021 | |
| Pfizer INC. | $55.06 | 2021 | |
| Esperion Therapeutics, INC. | $54.70 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.52 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $44.60 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.40 | 2021 | |
| Sanofi-Aventis U.S. LLC | $38.28 | 2021 | |
| Amarin Pharma, INC. | $37.90 | 2021 | |
| Sunovion Pharmaceuticals INC. | $32.26 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $27.69 | 2021 | |
| Grifols USA, LLC | $17.20 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $16.83 | 2021 | |
| Boston Scientific Corporation | $16.30 | 2021 | |
| Mylan Specialty L.P. | $14.58 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melanie Hughes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.